Anti-Integrin ⟪vb6 Antibody Titer as a Predictive Biomarker of Future Treatment Escalation in Patients With Ulcerative Colitis

被引：0

作者：

Yamamoto, Shuji ^{[1
]}

Kuwada, Shuji takeshi ^{[1
]}

Shiokawa, Masahiro ^{[1
]}

Kitamoto, Hiroki ^{[1
]}

Okabe, Makoto ^{[1
]}

Seno, Hiroshi ^{[1
]}

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, 54 Shogoin Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan

来源：

GASTRO HEP ADVANCES | 2025年 / 4卷 / 03期

关键词：

D O I：

10.1016/j.gastha.2024.10.022

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页数：3

共 38 条

[31] Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors
Zhang, Chun
Liu, Yuwang
Wang, Min
OYoung, Gilbert
Kavanagh, Joy
McFarlane, Cheryl
Cattaruzza, Fiore
Yeung, Pete
Cain, Jennifer
Yen, Wan-Ching
Fischer, Marcus
Cancilla, Belinda
Dobbin, Edwina
McCarthy, Michelle
Gurney, Austin
Faoro, Leonardo
Lewicki, John
Hoey, Tim
Kapoun, Ann M.
CANCER RESEARCH, 2016, 76
[32] Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate)
Sattler L.
Hanauer S.B.
Malter L.
Current Gastroenterology Reports, 2021, 23 (12)
[33] Diversity of peripheral CD8+PD-1+T cells is a novel predictive biomarker for response to anti-PD-1 antibody treatment in lung cancer patients
Matsumoto, Seiji
Matsutani, Takaji
Fujita, Yoshiko
Kitaura, Kazutaka
Nakamichi, Tohoru
Nakamura, Akifumi
Kuroda, Ayumi
Hashimoto, Masaki
Kondo, Nobuyuki
Suzuki, Ryuji
Hasegawa, Seiki
CANCER RESEARCH, 2019, 79 (13)
[34] Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody
Ikenouchi, Maiko
Fukui, Hirokazu
Yagi, Soichi
Nogami, Akira
Kaku, Koji
Sato, Toshiyuki
Kawai, Mikio
Kamikozuru, Koji
Yokoyama, Yoko
Takagawa, Tetsuya
Tomita, Toshihiko
Kobayashi, Taku
Shinzaki, Shinichiro
INTESTINAL RESEARCH, 2025,
[35] Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
Reinisch, W.
Sandborn, W. J.
Danese, S.
Hebuterne, X.
Klopocka, M.
Tarabar, D.
Vanasek, T.
Gregus, M.
Hellstern, P. A.
Kim, J. S.
Sparrow, M.
Gorelick, K. J.
Goetsch, M.
Bliss, C.
Gupta, C.
Cataldi, F.
Vermeire, S.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S58 - S59
[36] BIOMARKER AND PHARMACOKINETIC DATA FROM THE TURANDOT II OPEN-LABEL EXTENSION STUDY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN PATIENTS WITH ULCERATIVE COLITIS
Reinisch, Walter
Sandborn, William J.
Danese, Silvio
Hebuterne, Xavier
Klopocka, Maria
Tarabar, Dino
Vanasek, Tomas
Gregus, Milos
Hellstern, Paul
Kim, Joo Sung
Sparrow, Miles
Gorelick, Kenneth J.
Goetsch, Martina
Bliss, Caleb
Gupta, Charu
Cataldi, Fabio
Vermeire, Severine
GASTROENTEROLOGY, 2019, 156 (06) : S1105 - S1106
[37] Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study
Suzuki, Kenji
Sameshima, Yukinori
Yokoyama, Junji
Terai, Shuji
Yoneyama, Hiroyuki
Atreya, Raja
Neurath, Markus F.
Hibi, Toshifumi
Asakura, Hitoshi
INFLAMMATION AND REGENERATION, 2024, 44 (01)
[38] Correlation between peripheral CD8+PD-1+T cells diversity, tumor mutation burden (TMB) and T cell clones with anti-PD-1 antibody treatment of lung cancer patients: TCR repertoire as a novel predictive biomarker
Matsumoto, Seiji
Matsutani, Takaji
Fujita, Yoshiko
Kitaura, Kazutaka
Nakamura, Yukio
Nakamichi, Toru
Nakamura, Akifumi
Kuroda, Ayumi
Hashimoto, Masaki
Kondo, Nobuyuki
Shini, Tadasu
Suzuki, Ryuji
Hasegawa, Seiki
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 →